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A
 
BSTRACT
 
Corticosteroids and theophylline have been used
widely for the treatment of asthma. These two classes
of drugs appear to reduce the tissue infiltration of
eosinophils, predominant inflammatory cells in the
airways of asthmatic patients. Corticosteroids inhibit
the generation of both endothelial-activating Th2
cytokines (e.g. interleukin (IL)-4/IL-13) and eosinophil
growth factors (e.g. IL-5/granulocyte–macrophage
colony stimulating factor) and also attenuate the
effects of eosinophil growth factors on the differentia-
tion and prolonged survival of eosinophils. However,
corticosteroids modulate directly neither eosinophil
adhesiveness nor the expression of adhesion proteins
on endothelial cells 
 
in vitro
 
. Therefore, it is likely that
the inhibitory effect of corticosteroids on the tissue infil-
tration of eosinophils is the consequence of indirect
mechanisms, mainly via the inhibition of cytokines.
Interestingly, theophylline, which is generally accepted
as a bronchodilator, attenuates eosinophil adhesion
to endothelial cells 
 
in vitro
 
 at a clinically therapeutic
concentration. Furthermore, theophylline inhibits the
expression of intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1 on endothelial cells
that had been stimulated with IL-4 plus tumor necrosis
factor-
 
α
 
. Thus, theophylline possibly exerts an inhibi-
tory effect on both the adhesive property of eosinophils
and the expression of adhesion molecules on endo-
thelial cells. These findings possibly indicate that theo-
phylline would be adequate to supplement the actions
of corticosteroids in asthmatic airway inflammation,
partly via its inhibitory effect on the interaction between
blood eosinophils and endothelial cells.
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I
 
NTRODUCTION
 
Corticosteroids and theophylline have been used widely
for the treatment of asthma. There is increasing evidence
that not only corticosteroids, but also theophylline atten-
uates eosinophil accumulation in the airways of asth-
matic patients.
 
1–3
 
 For example, Sullivan 
 
et al
 
.
 
1
 
 have
reported that theophylline attenuates eosinophil airway
accumulation in response to allergen inhalation in
atopic asthma. More recently, Aizawa 
 
et al
 
.
 
2
 
 have shown
that theophylline treatment in mild to moderate asthma
resulted in a reduction in the percentage of eosinophils
from induced sputa. Similarly, Lim 
 
et al
 
.
 
3
 
 have found that
theophylline reduces the number of eosinophils in sputa,
biopsied specimens and bronchoalveolar lavage fluid in
mild asthmatic patients.
It is plausible that eosinophils are pivotal effector cells
in asthma. For example, recent evidence indicates that
the number and activation of eosinophils are reduced by
anti-interleukin (IL)-5 monoclonal antibody (mAb), result-
ing in the significant attenuation of extracellular matrix
protein deposition in the airway subepithelium of asth-
matic patients.
 
4
 
 Although the accumulation of eosi-
nophils into the airways of asthmatic patients depends on
multiple factors, including migration through tissue and
prolongation of cell survival, the initial step is the adhe-
sion of circulating eosinophils to vascular endothelial
cells. It is generally accepted that this process is mainly
mediated by the interaction between eosinophil integrin
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adhesion molecules, including 
 
α
 
4
 
 integrins such as
 
α
 
4
 
β
 
1
 
 (CD49d/CD29; VLA-4), 
 
β
 
2
 
 integrins such as 
 
α
 
L
 
β
 
2
 
(CD11a/cd18; LFA-1) and 
 
α
 
M
 
β
 
2
 
 (CD11b/CD18;
Mac-1), and their counterligands vascular cell adhesion
molecule (VCAM)-1 and intercellular adhesion mole-
cule (ICAM)-1 on endothelial cells.
 
5,6
 
 In the present
review, the mechanisms by which corticosteroids and
theophylline modulate eosinophil accumulation into the
airways of asthmatic patients are discussed. The author
focuses particularly on their effects on the adhesive
interaction between blood eosinophils and endothelial
cells.
 
E
 
FFECTS
 
 
 
OF
 
 
 
CORTICOSTEROIDS
 
 
 
ON
 
 
 
EOSINOPHILIC
 
 
 
INFLAMMATION
 
Corticosteroids are used as first-line drugs in the treat-
ment of bronchial asthma. Numerous studies have
revealed that corticosteroids decrease the number of
eosinophils and the expression of inflammatory cytokines
in the airways of asthmatic patients.
 
7
 
 Corticosteroids
attenuate the generation of Th2 cytokines, including IL-5
and CC chemokines.
 
8,9
 
 Corticosteroids also inhibit the
differentiation and prolonged survival of eosinophils
induced by growth factors such as IL-5
 
10
 
 and suppress
the migration of eosinophils 
 
in vitro
 
.
 
11,12
 
 Finally, there is
evidence that corticosteroids directly induce apoptosis of
eosinophils.
 
13,14
 
Sutani 
 
et al.
 
15
 
 and Kaiser 
 
et al
 
.
 
16
 
 have evaluated
whether corticosteroids modulate the adhesive inter-
action between blood eosinophils and endothelial cells.
In our study,
 
15
 
 dexamethasone did not inhibit the sponta-
neous or 
 
N
 
-Formyl-methionyl-leucyl-phenylalanine (FMLP)-
or IL-5-stimulated adhesion of eosinophils to endothelial
cells. These results are consistent with a previous report
using budesonide
 
16
 
 and suggest that corticosteroids are
devoid of a direct inhibitory effect on the adhesiveness of
eosinophils. We have also observed that dexamethasone
does not modify the expression of VCAM-1 or ICAM-1
on human pulmonary microvascular endothelial cells
stimulated with IL-4 and tumor necrosis factor (TNF)-
 
α
 
.
 
15
 
A previous study has also demonstrated that budesonide
fails to modify the expression of adhesion molecules on
cytokine-stimulated human umbilical vein endothelial
cells.
 
16
 
 Together, these results suggest that cortico-
steroids have no ability to modify the expression of adhe-
sion molecules on endothelial cells induced by cytokines.
Therefore, it is likely that the inhibitory effect of cortico-
steroids on the tissue infiltration of eosinophils is the
consequence of other effects, probably inhibition of
cytokine generation.
 
T
 
HEOPHYLLINE
 
 
 
ATTENUATES
 
 
 
ADHESIVE
 
 
 
INTERACTION
 
 
 
BETWEEN
 
 
 
EOSINOPHILS
 
 
 
AND
 
 
 
ENDOTHELIAL
 
 
 
CELLS
 
Traditionally, theophylline has been used as a broncho-
dilator to control the tone of airway smooth muscle in
asthmatic patients. More recently, theophylline has been
shown to induce a variety of inhibitory effects on inflam-
matory cells involved in asthmatic inflammation. In
eosinophils, theophylline accelerated apoptotic events
 
17
 
and attenuated both the release of specific granule
proteins
 
18,19
 
 and the surface expression of CD11b.
 
19
 
 In
this context, we evaluated whether theophylline modifies
the adhesive properties of blood eosinophils and the
expression of adhesion molecules on human umbilical
vein endothelial cells (HUVEC).
 
20
 
 Consequently, we
found that theophylline attenuated the IL-5- or FMLP-
stimulated adhesion of eosinophils to endothelial cells
(Fig. 1). This anti-inflammatory effect of theophylline
seems to be due, at least in part, to the inhibition of type
IV phosphodiesterase (PDE) because rolipram, a selec-
tive type IV PDE inhibitor, and 
 
N
 
6,2
 
′
 
-
 
O
 
-dibutyladenosine
(db)-cAMP, a cAMP analog, also attenuated eosinophil
adhesion to endothelial cells.
 
20
 
 We also observed that
theophylline attenuated the expression of ICAM-1 or
VCAM-1 on HUVEC that had been induced by IL-4 plus
TNF-
 
α
 
 (Fig. 2). These effects seemed to be observed at
therapeutically relevant concentrations of theophylline.
Collectively, these results suggest the potentially impor-
tant inhibitory effect of theophylline on the adhesive
interaction between circulating eosinophils and vascular
endothelial cells.
The adhesion molecule responsible for the effect of
theophylline on eosinophil adhesion is likely to be a
 
β
 
2
 
-integrin, because we have confirmed that FMLP- and
eosinophil growth factor-activated eosinophil adhesions
are 
 
β
 
2
 
-integrin dependent.
 
21
 
 In this context, theophylline
has been shown to attenuate the expression of CD11b, a
 
β
 
2
 
-integrin molecule on eosinophils.
 
19
 
 However, in the
 
β
 
2
 
-integrin-dependent adhesion of leukocytes, the activa-
tion state of this integrin may be more relevant than the
number of molecules expressed on the cell surface.
Therefore, we speculate that theophylline modulates
either the enhanced expression or conformational
change of 
 
β
 
2
 
-integrin that increases eosinophil ability for
cell adhesion.
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C
 
LINICAL
 
 
 
IMPLICATIONS
 
 
 
OF
 
 
 
THE
 
 
 
DIFFERENTIAL
 
 
 
EFFECT
 
 
 
OF
 
 
 
CORTICOSTEROIDS
 
 
 
AND
 
 
 
THEOPHYLLINE
 
 
 
ON
 
 
 
EOSINOPHILIC
 
 
 
INFLAMMATION
 
Our observations and evidence suggest that corticoster-
oids attenuate eosinophilic inflammation in asthma
mainly via the downregulation of cytokine production,
but have no direct action on eosinophil adhesiveness or
endothelial adhesion molecule expression. In contrast,
the direct modulatory effect of theophylline on the inter-
action between circulating eosinophils and endothelial
cells may be a novel mechanism for the attenuation of
eosinophil accumulation in the airways of asthmatic
patients. Although the exact impact of these inflammatory
 
Fig. 1
 
Effect of theophylline on eosinophil adhesion to human
umbilical vein endothelial cells induced by (a) 1 
 
µ
 
mol/L
 
N
 
-Formyl-methionyl-leucyl-phenylalanine or (b) 100 pmol/L
interluekin-5. Data are the mean 
 
±
 
 SEM (
 
n
 
 = 7). *
 
P
 
 < 0.05
compared with control; **
 
P
 
 < 0.001 compared with control
and 0.01 mmol/L theophyliine; ***
 
P
 
 < 0.001 compared with
the other three conditions. (Reproduced with the permission of
S Karger AG, Basel, from Choo 
 
et al.
 
20
 
)
 
Fig. 2 Effect of theophylline on the expression of (a) inter-
cellular adhesion molecule-1 or (b) vascular cell adhesion
molecule-1 on human umbilical vein endothelial cells stimu-
lated by the combination of interleukin-4 and tumor necrosis
factor-α (both at 100 pmol/L). Data are the mean ± SEM
(n = 5). *P < 0.05, **P < 0.01 compared with control;
P < 0.05 compared with 0.01 mmol/L theophylline. OD, opti-
cal density. (Reproduced with the permission of S Karger AG,
Basel, from Choo et al.20)
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properties on the clinical effects of theophylline remains
to be clarified, it is probable that the effects of theo-
phylline in asthma manifest eventually through a com-
bination of bronchodilatory and anti-inflammatory
properties.
The combination of inhaled corticosteroids and theo-
phylline has been shown to provide additive clinical and
physiological effects in moderate asthma,22 suggesting
that these two classes of drugs act via differential mecha-
nisms to modulate airway changes in asthma. Minoguchi
et al.23 have reported that the withdrawal of theophylline
in moderate asthmatic patients treated with inhaled corti-
costeroids resulted in an increase in sputum eosinophils,
raising the possibility that these two classes of drugs
specifically and differentially act to attenuate eosinophilic
infiltration. Theophylline would alter both the bronchial
smooth muscle tone and the accumulation and/or
functional state of eosinophils, thus potentially providing
additive benefits in asthmatic patients treated with
inhaled corticosteroids.
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